Article

Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics with a Bell-Shaped Efficacy Curve

2025-05-25

Abstract excerpt

Bispecific antibodies can be broadly divided into two categories: those that are pharmacologically active as either dimers bound to a single target or as trimers bound to both targets, and those that are only active as trimers. Dose selection of trimer-based bispecifics poses a unique challenge, as toxicity increases with dose, but efficacy does not. Instead, trimer-driven bispecifics have a bell-shaped efficacy c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7f990f61-f4af-5257-a211-82a397880d3a
DOI: 10.1101/2025.05.20.655186

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics with a Bell-Shaped Efficacy CurveDOI 10.1101/2025.05.20.655186Read

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approachesSemantic proximity Read

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profilingSemantic proximity Read

Deconvolution of clinical variance in CAR-T cell pharmacology and responseSemantic proximity Read

A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity Read

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read

Systematic De-Risking of TCR-Mimic Therapeutics Through Proteome-Wide Off-Target Landscaping and a Generalizable Design Rule FrameworkSemantic proximity Read

"Two-in-One" approach for bioassay selection for dual specificity antibodies.Semantic proximity Read

Teclistamab: Mechanism of action, clinical, and translational scienceSemantic proximity Read

Dual-Specific Antibody Design Using Artificial IntelligenceSemantic proximity Read